ReviewFrontiers in cell and developmental biology2024
Cell therapy in kidney diseases: advancing treatments for renal regeneration.
Review in Frontiers in cell and developmental biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Worldwide hotspots and trends in stem cell therapy for kidney disease in the last decade: a bibliometric and visualization analysis from 2015 to 2024.Frontiers in immunology · 2025Pooled it
- Application of ultrasound localization microscopy in the diagnosis and treatment of kidney diseases.Journal of ultrasound · 2026Review
- A Randomized Clinical Trial of Kidney Autologous Cell Therapy in Diabetic Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Cell and extracellular vesicle therapies for AKI in critical care: clinical translation, organ-support integration, and lessons learned.Frontiers in medicine · 2026Review
- Utilization of Stem Cells in Medicine: A Narrative Review.International journal of molecular sciences · 2025Review
- 3D Bioprinted Renal Constructs Using Kidney-Specific ECM Bioink System on Kidney Regeneration.Advanced healthcare materials · 2025Article
- Editorial: Stem cells and kidney regeneration: transforming renal medicine.Frontiers in bioengineering and biotechnology · 2025Article
- Therapeutic Applications of Induced Pluripotent Stem Cell Technology in Kidney Disease: A Systematic Review and Meta-Analysis.Kidney diseases (Basel, Switzerland)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD), pose a significant global health challenge, with high morbidity and mortality rates driven by rising prevalence of risk factors such as diabetes and hypertension. Current therapeutic strategies are often limited, prompting the exploration of advanced cell therapies as potential solutions. This review provides a comprehensive overview of the state of cell therapies in kidney disease, tracing the progression from preclinical studies to clinical applications. Recent studies highlited that cell-based interventions offer kidney-protective properties through mechanisms such as paracrine signaling, immune modulation, and direct tissue integration, demonstrating potential in both AKI and CKD settings. Despite promising results, challenges remain in optimizing cell therapy protocols, including cell sourcing, delivery methods, and long-term outcomes. Finally, the review addresses on efforts to enhance cell function, optimize dosing, and refine delivery techniques to improve clinical outcomes in kidney disease management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.